GGrantIndex
← Leaderboards

Gavin P. Robertson

Pennsylvania State Univ Hershey Med Ctr

$6,707,206
Attributed
$8,610,244
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY200624
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$8,610,244 · 7

By mechanism

R01$8,314,157 · 4
R03$293,019 · 2
P41$3,068 · 1

Top collaborators

Most similar at Pennsylvania State Univ Hershey Med Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Melanoma

Research focus

MelanomaTumorBasePathway InteractionsAnimalsInnovationProteinsCell SurvivalSignal TransductionKillingsCancer CellSkin CancerLeadMelanoma CellMediatingNeoplasm MetastasisPreventCellsChemopreventive AgentMutantPharmaceutical PreparationsStagingPre-ClinicalMouse Model

Grant awards (26)

Targeting Aldehyde Dehydrogenase for Cancer Prevention$558,440
R01 · FY2024 · CA · contact PI
Targeting Aldehyde Dehydrogenase for Cancer Prevention$587,645
R01 · FY2023 · CA · contact PI
Targeting Aldehyde Dehydrogenase for Cancer Prevention$600,507
R01 · FY2022 · CA · contact PI
Targeting Aldehyde Dehydrogenase for Cancer Prevention$628,206
R01 · FY2021 · CA · contact PI
Targeting Aldehyde Dehydrogenase for Cancer Prevention$125,000
R01 · FY2021 · CA · contact PI
Targeting Aldehyde Dehydrogenase for Cancer Prevention$641,281
R01 · FY2020 · CA · contact PI
Targeted Chemoprevention for Melanoma$394,108
R01 · FY2014 · CA · contact PI
Synergistically Acting Targeted Therapeutics for Melanoma$302,813
R01 · FY2014 · CA · contact PI
Targeted Chemoprevention for Melanoma$382,639
R01 · FY2013 · CA · contact PI
Synergistically Acting Targeted Therapeutics for Melanoma$293,448
R01 · FY2013 · CA · contact PI
Targeted Chemoprevention for Melanoma$407,854
R01 · FY2012 · CA · contact PI
Synergistically Acting Targeted Therapeutics for Melanoma$312,178
R01 · FY2012 · CA · contact PI
Akt3 Signaling as a Therapeutic Target$303,925
R01 · FY2012 · CA · contact PI
Targeted Chemoprevention for Melanoma$432,123
R01 · FY2011 · CA · contact PI
Synergistically Acting Targeted Therapeutics for Melanoma$312,178
R01 · FY2011 · CA · contact PI
Akt3 Signaling as a Therapeutic Target$303,925
R01 · FY2011 · CA · contact PI
NMR IMAGING OF IRON OXIDE NANOPARTICLES$3,068
P41 · FY2011 · RR · contact PI
Targeted Chemoprevention for Melanoma$466,079
R01 · FY2010 · CA · contact PI
Synergistically Acting Targeted Therapeutics for Melanoma$321,833
R01 · FY2010 · CA · contact PI
Akt3 Signaling as a Therapeutic Target$313,325
R01 · FY2010 · CA · contact PI
Akt3 Signaling as a Therapeutic Target$313,325
R01 · FY2009 · CA · contact PI
Akt3 Signaling as a Therapeutic Target$313,325
R01 · FY2008 · CA · contact PI
Targeted Chemoprevention Through Inhibition of Akt3 Signaling$75,500
R03 · FY2008 · CA · contact PI
Targeted Chemoprevention Through Inhibition of Akt3 Signaling$75,500
R03 · FY2007 · CA · contact PI
Melanoma Chemoprevention by Targeting Mutant (V600E) B-Raf$69,947
R03 · FY2007 · CA · contact PI
Melanoma Chemoprevention by Targeting Mutant (V600E) B-Raf$72,072
R03 · FY2006 · CA · contact PI